您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Skp2 inhibitor C1(SKPin C1)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Skp2 inhibitor C1(SKPin C1)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Skp2 inhibitor C1(SKPin C1)图片
CAS NO:432001-69-9
规格:≥98%
包装与价格:
包装价格(元)
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 465.34
Formula C18H13BrN2O4S2
CAS No. 432001-69-9
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 93 mg/mL (199.85 mM)
Water: < 1mg/mL
Ethanol: < 1mg/mL
Chemical Name 2-[4-Bromo-2-[[4-oxo-3-(3-pyridinylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]phenoxy]acetic acid
Synonyms Skp2 inhibitor C1; SKPin C1
SMILES Code O=C(O)COC1=CC=C(Br)C=C1/C=C(SC(N2CC3=CC=CN=C3)=S)/C2=O
实验参考方法
In Vitro

In vitro activity: Skp2 inhibitor C1 treatment of MCF-7 breast cancer cells lines does not increase, but rather decrease the percentage of cells in G1 while increasing the G2/M population. T47D cells treated with C1 (5 μM for 16 hours) displayed an increase in G1 phase (p < 0.0001) and a decrease in S phase (p < 0.0001), correlating with p27 protein induction. In contrast, MCF-7 cells responded to C1 with a significant reduction in G1 phase (35%, p < 0.0001) and an increase in G2-M phase (43%, p < 0.0001). This G1 reduction and G2/M arrest is dose dependent on C1 (Figure 5C right; p < 0.001 and p < 0.01, respectively) and correlates with increased p27 protein levels.


Kinase Assay: Skp2 inhibitor C1 treatment of MCF-7 breast cancer cells lines does not increase, but rather decrease the percentage of cells in G1 while increasing the G2/M population. T47D cells treated with C1 (5 μM for 16 hours) displayed an increase in G1 phase (p < 0.0001) and a decrease in S phase (p < 0.0001), correlating with p27 protein induction. In contrast, MCF-7 cells responded to C1 with a significant reduction in G1 phase (35%, p < 0.0001) and an increase in G2-M phase (43%, p < 0.0001). This G1 reduction and G2/M arrest is dose dependent on C1 (Figure 5C right; p < 0.001 and p < 0.01, respectively) and correlates with increased p27 protein levels.


Cell Assay: 501 Mel cell lines are pretreated with each inhibitor (10 μM) or 0.1% DMSO (vehicle) for 16 h. Cycloheximide half-life is examined. T47D cells treated with C1 (5 μM for 16 hours) displayed an increase in G1 phase (p < 0.0001) and a decrease in S phase (p < 0.0001), correlating with p27 protein induction. In contrast, MCF-7 cells responded to C1 with a significant reduction in G1 phase (35%, p < 0.0001) and an increase in G2-M phase (43%, p < 0.0001). This G1 reduction and G2/M arrest is dose dependent on C1 (Figure 5C right; p < 0.001 and p < 0.01, respectively) and correlates with increased p27 protein levels (Figure 5E left, S4A top right.

In Vivo
Animal model
Formulation & Dosage
References Chem Biol. 2012 Dec 21; 19(12): 1515–1524.; Endocrinology. 2013 Nov;154(11):4030-45.